{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:05:47Z","timestamp":1771257947190,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["21249084"],"award-info":[{"award-number":["21249084"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Japan National Society for the Prevention of Blindness","award":["22791653"],"award-info":[{"award-number":["22791653"]}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.ajo.2012.01.010","type":"journal-article","created":{"date-parts":[[2012,3,31]],"date-time":"2012-03-31T20:35:50Z","timestamp":1333226150000},"page":"125-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Factors Associated With the Response of Age-Related Macular Degeneration to Intravitreal Ranibizumab Treatment"],"prefix":"10.1016","volume":"154","author":[{"given":"Kenji","family":"Yamashiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoruko","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akitaka","family":"Tsujikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Akagi-Kurashige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sotaro","family":"Ooto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagahisa","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ajo.2012.01.010_bib1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ajo.2009.02.012","article-title":"Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy","volume":"148","author":"Cho","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2012.01.010_bib2","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ajo.2010.05.035","article-title":"Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab","volume":"150","author":"Stangos","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2012.01.010_bib3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1177\/112067210801800427","article-title":"Short-term anatomic effect of ranibizumab for polypoidal choroidal vasculopathy","volume":"18","author":"Reche-Frutos","year":"2008","journal-title":"Eur J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2012.01.010_bib4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000175312","article-title":"Short-term safety and efficacy of a single intravitreal bevacizumab injection for the management of polypoidal choroidal vasculopathy","volume":"223","author":"Song","year":"2009","journal-title":"Ophthalmologica"},{"issue":"5","key":"10.1016\/j.ajo.2012.01.010_bib5","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ajo.2010.05.026","article-title":"Improvement of angiographic findings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3 months","volume":"150","author":"Hikichi","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2012.01.010_bib6","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/IAE.0b013e3181f84fdf","article-title":"One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy","volume":"31","author":"Cheng","year":"2011","journal-title":"Retina"},{"issue":"8","key":"10.1016\/j.ajo.2012.01.010_bib7","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1097\/IAE.0b013e31820d3f3f","article-title":"Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy","volume":"31","author":"Lai","year":"2011","journal-title":"Retina"},{"issue":"8","key":"10.1016\/j.ajo.2012.01.010_bib8","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/IAE.0b013e31820f4b21","article-title":"Intravitreal ranibizumab for polypoidal choroidal vasculopathy with recurrent or residual exudation","volume":"31","author":"Saito","year":"2011","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.ajo.2012.01.010_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","article-title":"Clinical characteristics of exudative age-related macular degeneration in Japanese patients","volume":"144","author":"Maruko","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2012.01.010_bib10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000221837","article-title":"Comparative assessment of photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a multicenter study in Hyogo prefecture, Japan","volume":"223","author":"Honda","year":"2009","journal-title":"Ophthalmologica"},{"issue":"11","key":"10.1016\/j.ajo.2012.01.010_bib11","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1167\/iovs.10-5554","article-title":"CFH and ARMS2 variations in age-related macular degeneration, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation","volume":"51","author":"Hayashi","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.ajo.2012.01.010_bib12","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ophtha.2010.09.001","article-title":"Vitreomacular interface in typical exudative age-related macular degeneration and polypoidal choroidal vasculopathy","volume":"118","author":"Nomura","year":"2011","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2012.01.010_bib13","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s00417-011-1620-1","article-title":"Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy","volume":"249","author":"Koizumi","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2012.01.010_bib14","first-page":"977","article-title":"The association of age-related maculopathy susceptibility 2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy","volume":"17","author":"Bessho","year":"2011","journal-title":"Mol Vis"},{"issue":"10","key":"10.1016\/j.ajo.2012.01.010_bib15","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1097\/IAE.0b013e3181e587e3","article-title":"Association of LOC387715 A69S genotype with visual prognosis after photodynamic therapy for polypoidal choroidal vasculopathy","volume":"30","author":"Sakurada","year":"2010","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.ajo.2012.01.010_bib16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ophtha.2010.04.007","article-title":"Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration","volume":"118","author":"Tsuchihashi","year":"2011","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2012.01.010_bib17","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ophtha.2006.10.045","article-title":"Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration","volume":"114","author":"Boyer","year":"2007","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2012.01.010_bib18","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ajo.2007.08.012","article-title":"Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results","volume":"144","author":"Kaiser","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2012.01.010_bib19","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10384-010-0864-3","article-title":"Intravitreal bevacizumab for age-related macular degeneration with good visual acuity","volume":"54","author":"Takahashi","year":"2010","journal-title":"Jpn J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2012.01.010_bib20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1755-3768.2009.01843.x","article-title":"EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration","volume":"88","author":"Tano","year":"2010","journal-title":"Acta Ophthalmol"},{"issue":"14","key":"10.1016\/j.ajo.2012.01.010_bib21","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ajo.2012.01.010_bib22","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ajo.2012.01.010_bib23","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","article-title":"An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration","volume":"143","author":"Fung","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2012.01.010_bib24","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0002-9394(02)01404-6","article-title":"Polypoidal choroidal vasculopathy: natural history","volume":"133","author":"Uyama","year":"2002","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2012.01.010_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.survophthal.2003.10.007","article-title":"Polypoidal choroidal vasculopathy","volume":"49","author":"Ciardella","year":"2004","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2012.01.010_bib26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000329466","article-title":"One-year results of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy","volume":"226","author":"Song","year":"2011","journal-title":"Ophthalmologica"},{"issue":"3","key":"10.1016\/j.ajo.2012.01.010_bib27","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/bjo.2008.150029","article-title":"Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results","volume":"94","author":"Kokame","year":"2011","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2012.01.010_bib28","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/bjo.2007.122283","article-title":"Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy","volume":"92","author":"Gomi","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2012.01.010_bib29","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s10384-010-0813-1","article-title":"Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab","volume":"54","author":"Tsujikawa","year":"2011","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2012.01.010_bib30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ajo.2007.03.014","article-title":"Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy","volume":"144","author":"Otani","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2012.01.010_bib31","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.ophtha.2007.09.008","article-title":"Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab","volume":"114","author":"Brantley","year":"2007","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2012.01.010_bib32","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1167\/iovs.10-6080","article-title":"Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD","volume":"52","author":"Kloeckener-Gruissem","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.ajo.2012.01.010_bib33","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1111\/j.1755-3768.2010.02080.x","article-title":"Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration","volume":"89","author":"Nischler","year":"2011","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2012.01.010_bib34","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1136\/bjo.2010.193680","article-title":"CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration","volume":"96","author":"McKibbin","year":"2012","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2012.01.010_bib35","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/bjo.2008.150995","article-title":"Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab","volume":"93","author":"Lee","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2012.01.010_bib36","first-page":"2598","article-title":"Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration","volume":"16","author":"Teper","year":"2010","journal-title":"Mol Vis"},{"issue":"2","key":"10.1016\/j.ajo.2012.01.010_bib37","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12177-010-9055-1","article-title":"CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration","volume":"3","author":"Imai","year":"2010","journal-title":"J Ocul Biol Dis Infor"},{"issue":"2","key":"10.1016\/j.ajo.2012.01.010_bib38","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ophtha.2010.06.040","article-title":"Complement factor H Y402H variant and risk of age-related macular degeneration in Asians: a systematic review and meta-analysis","volume":"118","author":"Kondo","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2012.01.010_bib39","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2147\/OPTH.S12577","article-title":"Combined photodynamic therapy and intravitreal bevacizumab for idiopathic polypoidal choroidal vasculopathy: one-year follow-up","volume":"4","author":"Romano","year":"2010","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2012.01.010_bib40","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ajo.2011.07.001","article-title":"Treatment of polypoydal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab","volume":"153","author":"Tomita","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2012.01.010_bib41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000236040","article-title":"Clinical features of polypoidal choroidal vasculopathy and visual outcomes in the absence of classic choroidal neovascularization","volume":"224","author":"Yamaoka","year":"2010","journal-title":"Ophthalmologica"},{"issue":"11","key":"10.1016\/j.ajo.2012.01.010_bib42","doi-asserted-by":"crossref","first-page":"8063","DOI":"10.1167\/iovs.11-7820","article-title":"Association of genetic variation on chromosome 9p21 with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration","volume":"52","author":"Zhang","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939412000438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939412000438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:39:44Z","timestamp":1762079984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939412000438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0002939412000438"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2012.01.010","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors Associated With the Response of Age-Related Macular Degeneration to Intravitreal Ranibizumab Treatment","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2012.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}